title: Comparison of helodermin, VIP and PHI in pancreatic secretion and blood flow in dogs.
abstract: Helodermin, VIP and PHI, which share a high degree of homology with secretin, have been identified in the gut but their physiological role is unknown. In this study 3 series of tests were carried out to determine the actions of helodermin, VIP and PHI on pancreatic secretion in 6 conscious dogs and amylase release from the dispersed canine pancreatic acini and to correlate the alterations in pancreatic secretory and circulatory effects in 24 anesthetized dogs. Helodermin, VIP and PHI infused i.v. in graded doses (12.5-200 pmol/kg.h) resulted in a dose-dependent increase in pancreatic HCO3 secretion reaching, respectively, 100%, 7% and 2% of secretin maximum. When combined with constant dose infusion of CCK-8 (100 pmol/kg.h), helodermin but not VIP or PHI augmented dose-dependently the HCO3 secretion. When added in various concentrations (10(-10)-10(-5)M) to the incubation medium of dispersed pancreatic acini only helodermin but not VIP or PHI increased dose-dependently amylase release reaching about 50% of CCK-8 maximum. In anesthetized dogs, the pancreatic blood flow (PBF) measured by electromagnetic blood flowmetry showed an immediate and dose-dependent increase following the injections of various doses of helodermin, VIP, PHI and secretin, the peak blood flow preceding by about 1 min the peak secretory stimulation. This study shows that helodermin resembles secretin in its potent pancreatic HCO3 stimulation but differs from VIP or PHI which are poor secretagogues but potent vasodilators. We conclude that if tested peptides are released in the gut, helodermin, like secretin, may be involved in the hormonal stimulation of exocrine pancreas, whereas VIP and PHI may serve mainly as vasodilators in the pancreatic circulation.
authors.affiliation: Institute of Physiology, Academy of Medicine, Krakow, Poland.
authors.forename: S J
authors.initials: SJ
authors.lastname: Konturek
authors.forename: N
authors.initials: N
authors.lastname: Yanaihara
authors.forename: W
authors.initials: W
authors.lastname: Pawlik
authors.forename: J
authors.initials: J
authors.lastname: Jaworek
authors.forename: K
authors.initials: K
authors.lastname: Szewczyk
mesh_terms: D000818:Animals; D002766:Cholecystokinin / Q000097:blood / Q000378:metabolism; D004285:Dogs; D005755:Gastrins / Q000097:blood / Q000378:metabolism; D036341:Intercellular Signaling Peptides and Proteins; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D010451:Peptide PHI / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D012633:Secretin / Q000097:blood / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
chemical_list: D005755:Gastrins; D036341:Intercellular Signaling Peptides and Proteins; D010451:Peptide PHI; D010455:Peptides; D011506:Proteins; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; C040442:heliodermin; D002766:Cholecystokinin